This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
by Ekta Bagri
BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
by Zacks Equity Research
ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.
BAYRYPositive Net Change LXRXNegative Net Change AMRNNegative Net Change ZTSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
by Zacks Equity Research
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
BAYRYPositive Net Change LXRXNegative Net Change AMRNNegative Net Change LYRANegative Net Change
biotechnology biotechs medical pharmaceuticals
Hudson Technologies (HDSN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
HDSNNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy SES AI Corporation (SES) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SESNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
by Zacks Equity Research
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.
REGNPositive Net Change SNYNegative Net Change NVOPositive Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
by Zacks Equity Research
Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.
JNJPositive Net Change BAYRYPositive Net Change LXRXNegative Net Change AMRNNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
by Zacks Equity Research
Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.
SNYNegative Net Change BAYRYPositive Net Change LXRXNegative Net Change AMRNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
by Urmimala Biswas
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
BSXPositive Net Change AMGNPositive Net Change DXCMPositive Net Change ABBVNegative Net Change CTREPositive Net Change CHCTNegative Net Change
biotechnology biotechs healthcare medical medical-devices pharmaceuticals
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?
by Zacks Equity Research
EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations.
BMYPositive Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers Collaborates With BNTX for Oncology Candidate
by Zacks Equity Research
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.
NVSPositive Net Change BMYPositive Net Change PFEPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
by Zacks Equity Research
KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.
SNYNegative Net Change LXRXNegative Net Change AMRNNegative Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Sterling Infrastructure (STRL) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
STRLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
by Zacks Equity Research
AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.
AMGNPositive Net Change BAYRYPositive Net Change LXRXNegative Net Change AMRNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
by Zacks Equity Research
SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.
SNYNegative Net Change BAYRYPositive Net Change AMRNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for Krystal Biotech Stock Options
by Zacks Equity Research
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
KRYSPositive Net Change
biotechnology biotechs medical
Strattec Security (STRT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
STRTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
TMDXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
by Zacks Equity Research
GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard care.
NVSPositive Net Change PFEPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
by Ekta Bagri
GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However, we recommend investors remain on the sidelines at current levels.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
by Zacks Equity Research
Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Marqeta (MQ) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
MQNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
by Zacks Equity Research
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
BAYRYPositive Net Change LXRXNegative Net Change AMRNNegative Net Change IMVTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
by Zacks Equity Research
ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.
JNJPositive Net Change BAYRYPositive Net Change AMRNNegative Net Change ORICNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals